PRESS RELEASE published on 02/01/2024 at 12:30, 9 months 20 days ago Immunic to Participate in Investor and Scientific Conferences in February Immunic, Inc. (Nasdaq: IMUX) to participate in BioCapital Europe 2024 and ACTRIMS Forum 2024 in February and March, presenting clinical pipeline therapies and poster presentations Immunic, Inc. BioCapital Europe 2024 ACTRIMS Forum 2024 Clinical Pipeline Therapies Poster Presentations
PRESS RELEASE published on 11/02/2023 at 11:30, 1 year ago Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts
PRESS RELEASE published on 10/26/2023 at 12:30, 1 year ago Immunic to Participate in Scientific and Industry Conferences in November
PRESS RELEASE published on 10/16/2023 at 12:30, 1 year 1 month ago Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023
PRESS RELEASE published on 10/15/2023 at 12:30, 1 year 1 month ago Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023
PRESS RELEASE published on 10/11/2023 at 12:30, 1 year 1 month ago Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting
PRESS RELEASE published on 10/09/2023 at 22:01, 1 year 1 month ago Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
PRESS RELEASE published on 10/04/2023 at 12:30, 1 year 1 month ago Immunic to Participate in Scientific Conferences in October
PRESS RELEASE published on 09/06/2023 at 12:30, 1 year 2 months ago Immunic to Participate in Industry and Investor Conferences in September
PRESS RELEASE published on 08/17/2023 at 12:30, 1 year 3 months ago Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
Published on 11/21/2024 at 12:00, 43 minutes ago Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 43 minutes ago Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 13 minutes ago FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 40 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 43 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 12:35, 8 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 28 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 11:30, 1 hour 13 minutes ago APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 06:58, 5 hours 45 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 45 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 45 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 36 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 23 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
